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Background
Overlapping Gag peptides have demonstrated potential in
stimulating T cell immunity and slowing the progression
of AIDS. However, peptides administered alone are
poorly immunogenic and rapidly degraded in vivo before
they can reach antigen presenting cells (APCs). Hence,
novel technologies that can efficiently deliver antigens to
APCs are desperately needed to create safe and effective
vaccines. Nanoengineered Layer-by-Layer capsules repre-
sent a novel technology for the delivery and protection of
protein/peptide antigens. The flexibility and multi-func-
tionality of this technology allows for fine-tuning of the
capsules to facilitate efficient delivery to APCs and opti-
mize immune responses.
Methods
Capsules were assembled from biodeconstructible poly-
mers that ensure the cargo is only released from the cap-
sules once within cells. Model protein/peptide vaccines
were encapsulated and assessed for internalization, DC
activation and T cell stimulation in vitro and in vivo using
human blood, murine models and macaques.
Results
Whole proteins and small peptides were successfully
encapsulated within biodeconstructible capsules. Cap-
sules were internalized by important APCs such as den-
dritic cells (DCs). Furthermore, DCs that associated with
capsules demonstrated an increase in activation markers
(CD86, CD83 and MHC-II). Protein/peptide loaded cap-
sules administered to mice activated CD4 and CD8 T cells.
Administration of capsules containing SIV peptides to SIV
infected macaques demonstrated re-activation of SIV-spe-
cific CD4 T cell responses and to a lesser extent CD8 T cell
responses.
Conclusion
These results demonstrate proof of concept for this novel
vaccine delivery technology and pave the way for future
experiments encapsulating overlapping SIV peptides for
the vaccination of macaques to assess the immunogenic-
ity and protective efficacy of this approach. Work is under-
way to further optimize this technology through surface
functionalization to specifically target DCs and by incor-
porating adjuvants. This multidisciplinary project repre-
sents a novel and exciting advance in vaccine delivery that
could have a major impact on HIV/AIDS.
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